0.95Open0.95Pre Close0 Volume2 Open Interest17.50Strike Price0.00Turnover71.92%IV5.43%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.95Extrinsic Value100Contract SizeAmericanOptions Type-0.4625Delta0.1386Gamma15.56Leverage Ratio-0.0294Theta-0.0043Rho-7.19Eff Leverage0.0159Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet